Jie Zheng1, Yu Wan, Abdelbary Elhissi, Zhirong Zhang, Xun Sun. 1. Key Laboratory of Drug Targeting and Drug Delivery Systems Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Abstract
PURPOSE: To develop a tumor-targeted drug delivery system based on solid lipid nanoparticles (SLNs) conjugated with the enzymatically cleavable polyethylene glycol (PEG). METHODS: SLNs loaded with paclitaxel (PTX) were prepared using the film ultrasonication method, followed by conjugation with a PEGylated peptide (Pp) that can specifically interact with matrix metalloproteinases (MMPs) that is over-expressed by tumor cells. The physicochemical characteristics of the Pp-PTX-SLNs were studied and the in vitro drug release, cytotoxicity and cell uptake of the formulations were investigated. Furthermore, using an animal model, the pharmacokinetic properties, biodistribution and anti-tumor activity of this system were evaluated. RESULTS: The resulting Pp-PTX-SLNs penetrated through tumor cells via facilitated uptake mediated by MMPs. The uncleavable Pp'-PTX-SLNs showed a lower cell uptake efficiency, compared with the Pp-PTX-SLNs. In a tumor-bearing mice model, Pp-PTX-SLNs accumulated to a greater extent at the tumor location, persisted longer in blood circulation, and showed lower toxicity than did PTX-SLNs or Taxol®. Most importantly, the mice treated with Pp-PTX-SLNs survived longer than the groups treated with Pp'-PTX-SLNs, PTX-SLNs or Taxol®. CONCLUSIONS: These results suggest that Pp-PTX-SLNs hold promise as a new strategy for paclitaxel chemotherapy, and that Pp-SLNs can be a useful nanocarrier for other chemotherapeutic drugs.
PURPOSE: To develop a tumor-targeted drug delivery system based on solid lipid nanoparticles (SLNs) conjugated with the enzymatically cleavable polyethylene glycol (PEG). METHODS: SLNs loaded with paclitaxel (PTX) were prepared using the film ultrasonication method, followed by conjugation with a PEGylated peptide (Pp) that can specifically interact with matrix metalloproteinases (MMPs) that is over-expressed by tumor cells. The physicochemical characteristics of the Pp-PTX-SLNs were studied and the in vitro drug release, cytotoxicity and cell uptake of the formulations were investigated. Furthermore, using an animal model, the pharmacokinetic properties, biodistribution and anti-tumor activity of this system were evaluated. RESULTS: The resulting Pp-PTX-SLNs penetrated through tumor cells via facilitated uptake mediated by MMPs. The uncleavable Pp'-PTX-SLNs showed a lower cell uptake efficiency, compared with the Pp-PTX-SLNs. In a tumor-bearing mice model, Pp-PTX-SLNs accumulated to a greater extent at the tumor location, persisted longer in blood circulation, and showed lower toxicity than did PTX-SLNs or Taxol®. Most importantly, the mice treated with Pp-PTX-SLNs survived longer than the groups treated with Pp'-PTX-SLNs, PTX-SLNs or Taxol®. CONCLUSIONS: These results suggest that Pp-PTX-SLNs hold promise as a new strategy for paclitaxel chemotherapy, and that Pp-SLNs can be a useful nanocarrier for other chemotherapeutic drugs.
Authors: Ilia Rivkin; Keren Cohen; Jacob Koffler; Dina Melikhov; Dan Peer; Rimona Margalit Journal: Biomaterials Date: 2010-06-17 Impact factor: 12.479
Authors: C Allen; N Dos Santos; R Gallagher; G N C Chiu; Y Shu; W M Li; S A Johnstone; A S Janoff; L D Mayer; M S Webb; M B Bally Journal: Biosci Rep Date: 2002-04 Impact factor: 3.840
Authors: María Carmen Leiva; Raúl Ortiz; Rafael Contreras-Cáceres; Gloria Perazzoli; Iryna Mayevych; Juan Manuel López-Romero; Francisco Sarabia; Jose Manuel Baeyens; Consolación Melguizo; Jose Prados Journal: Sci Rep Date: 2017-10-18 Impact factor: 4.379